EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Mechanisms and clinical applications of palmitoylethanolamide (PEA) in the treatment of neuropathic pain

Ardra Das, Preetha Balakrishnan

Inflammopharmacology · 2025

DOI: 10.1007/s10787-024-01623-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Inflammopharmacology, 2025. Verfasst von Ardra Das und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research and Development, First Floor, Molecules Biolabs Private Limited, Commercial Building Kinfra, 3/634Konoor Road, Muringur, Vadak…. Hauptthemen laut MEDLINE: Palmitic Acids, Ethanolamines, Neuralgia. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Palmitoylethanolamide (PEA) is emerging as a promising therapeutic agent for neuropathic and other pain-related conditions. This naturally occurring fatty acid has drawn interest because of its ability to regulate pain and inflammation. Initially identified in food sources, PEA has been the subject of extensive research to elucidate its properties, efficacy, and clinical applications. PEA primarily exerts its effects through interaction with its primary receptor PPAR α, this interaction influences pain signalling pathways and neuroinflammatory processes by modulating the synthesis of pro-inflammatory cytokines, mast cell degranulation, microglial activation, and decrease of oxidative stress. PEA's interaction with endocannabinoid receptors decreases the inflammatory cytokine and chemokine production and thereby a descending pain sensation. The pharmacological and pharmacokinetic characteristics of PEA are examined in this paper, along with its potential for efficiency when used in in combination additional therapies in a variety of neurodegenerative disease models, including multiple sclerosis, Parkinson's disease, and Alzheimer's. Experimental evidence shows that PEA not only reduces pain and inflammation but also lowers the need for higher dosages of other drugs hence minimizing the risk of drug toxicity. The bioavailability of PEA has been enhanced by recent technological developments, which emphasize continuous research efforts to maximize PEA's therapeutic potential in pain treatment and associated medical sectors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Palmitic AcidsEthanolaminesNeuralgiaHumansAnimalsAmidesEndocannabinoidsInflammationPPAR alphaOxidative Stress

Stichwörter der Autor:innen

ClinicalInflammationMast cell degranulationNeuropathicPEAPainTissue repair

Substanzen

palmidrolPalmitic AcidsEthanolaminesAmidesEndocannabinoidsPPAR alpha

Autor:innen und Institutionen

  • Department of Research and Development, First Floor, Molecules Biolabs Private Limited, Commercial Building Kinfra, 3/634Konoor Road, Muringur, Vadakkummuri, Koratty, Mukundapuram, Thrissur, Kerala, 680309, India.
  • Department of Research and Development, First Floor, Molecules Biolabs Private Limited, Commercial Building Kinfra, 3/634Konoor Road, Muringur, Vadakkummuri, Koratty, Mukundapuram, Thrissur, Kerala, 680309, India. b.pre…

Zitieren

APA

Das, A., & Balakrishnan, P. (2025). Mechanisms and clinical applications of palmitoylethanolamide (PEA) in the treatment of neuropathic pain. Inflammopharmacology. https://doi.org/10.1007/s10787-024-01623-8

Vancouver

Das A, Balakrishnan P. Mechanisms and clinical applications of palmitoylethanolamide (PEA) in the treatment of neuropathic pain. Inflammopharmacology. 2025. doi:10.1007/s10787-024-01623-8

BibTeX
@article{Das2025,
  author = {Das, Ardra and Balakrishnan, Preetha},
  title = {Mechanisms and clinical applications of palmitoylethanolamide (PEA) in the treatment of neuropathic pain},
  journal = {Inflammopharmacology},
  year = {2025},
  doi = {10.1007/s10787-024-01623-8}
}
Kostenlos starten →